779 results match your criteria Pruritus and Systemic Disease


Evaluating crisaborole as a treatment option for atopic dermatitis.

Expert Opin Pharmacother 2019 Apr 19:1-7. Epub 2019 Apr 19.

d Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Introduction: Atopic dermatitis (AD) is a chronic and recurrent disease presenting with eczematous lesions and pruritus. It impacts patient and family quality of life, increases morbidity, and accounts for large health-care expenditures. Although nonpharmacologic, topical, and systemic treatments exist, management of AD remains challenging due to limited treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1604688DOI Listing

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Br J Cancer 2019 Apr 17. Epub 2019 Apr 17.

Sarah Cannon Research Institute, London, UK.

Background: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy.

Methods: This dose-finding phase Ib study (adaptive 3 + 3 design) determined the maximum tolerated dose (MTD) of trametinib and the FAK inhibitor GSK2256098 in combination. Eligible patients had mesothelioma or other solid tumours with probable mitogen activated protein kinase pathway activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0452-3DOI Listing

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Aliment Pharmacol Ther 2019 Apr 12. Epub 2019 Apr 12.

Vienna, Austria.

Background: Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma.

Aim: To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma.

Methods: Sixty-five patients treated with nivolumab (n = 34) or pembrolizumab (n = 31) between July 10, 2015 and December 31, 2018 (data cut-off) across six centres in Austria and Germany were retrospectively analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15245DOI Listing

Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral center.

J Eur Acad Dermatol Venereol 2019 Apr 8. Epub 2019 Apr 8.

Department of Dermato-venereology, Bispebjerg Hospital, University of Copenhagen, Denmark.

Background: Management of moderate-to severe atopic dermatitis (AD) frequently requires treatment with systemic therapies. Dupilumab is the first biological agent approved for treatment of moderate-to severe AD. Although promising results have appeared in clinical trials, real-life data on efficacy and safety are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15609DOI Listing
April 2019
1 Read

Notalgia Paresthetica: Treatment Review and Algorithmic Approach.

J Dermatolog Treat 2019 Apr 3:1-27. Epub 2019 Apr 3.

a University of Central Florida College of Medicine , 6850 Lake Nona Blvd , Orlando , FL USA 32827.

Background: Notalgia Paresthetica (NP) is a sensory neuropathy of the back characterized by a well-demarcated, hyperpigmented macule or patch located medial or inferior to the scapulae. Symptoms include localized pruritus and pain, and the clinical course consists of remissions and relapses. It can be an underrecognized and difficult disease to treat since conventional treatments for pruritus in inflammatory dermatosis have variable efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1603360DOI Listing
April 2019
6 Reads

European S2k Guideline on Chronic Pruritus.

Acta Derm Venereol 2019 Apr;99(5):469-506

Occupational Dermatology, Department of Dermatology, Ruprecht-Karls University Heidelberg, Voßstr. 2, DE-69115 Heidelberg, Germany. E-mail:

Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis patients to 100% in skin diseases such as urticaria and atopic dermatitis (AD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3164DOI Listing
April 2019
2 Reads

Chronic Urticaria: An Overview of Treatment and Recent Patents.

Recent Pat Inflamm Allergy Drug Discov 2019 Mar 28. Epub 2019 Mar 28.

The Institute of Integrative Medicine, The Chinese University of Hong Kong, Shatin. Hong Kong.

Background: Up to 1% of the general population in the USA and Europe have chronic urticaria (CU) at some point in their lifetime. CU has an adverse effect on quality of life.

Objective: To provide an update on the epidemiology, pathogenesis, clinical manifestations, diagnosis, aggravating factors, complications, treatment and prognosis of CU. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1872213X13666190328164931DOI Listing
March 2019
1 Read

Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus.

Cytokine 2019 Mar 20;119:95-112. Epub 2019 Mar 20.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Vasco de Quiroga No. 15, Colonia Belisario Domínguez Sección XVI, 14080 Mexico City, Mexico. Electronic address:

We compared the chemokine/receptor expression in skin biopsies of discoid (SLE/DLE) and subacute lupus (SLE/SCLE) and correlated it with tissue and circulating effector CD4 T cells/regulatory cells. Skin biopsies and peripheral blood from 9 active SLE/DLE patients, 9 SLE/SCLE patients, 5 control SLE patients without cutaneous lesions and 10 control healthy donors were included. Clinical skin activity was measured by Cutaneous Lupus Erythematosus Disease Area and Severity Index scoring, and systemic activity was measured by a modified SLEDAI-2K excluding the cutaneous items. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2019.03.010DOI Listing
March 2019
1 Read

The use of naltrexone in dermatology. Current evidence and future directions.

Curr Drug Targets 2019 Mar 18. Epub 2019 Mar 18.

Department of Dermatology, Medical University of Warsaw, Warsaw. Poland.

Naltrexone is a competitive opioid receptor antagonist approved as supportive treatment in alcohol dependence and opioid addiction. In a dose 50-100 mg daily, naltrexone is used off-label in dermatology for the treatment of trichotillomania and different types of pruritus. At a dose as low as 1-5 mg of drug per day, naltrexone demonstrates immunomodulatory action i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450120666190318121122DOI Listing
March 2019
12 Reads

[Epidermolysis bullosa acquisita].

Hautarzt 2019 Apr;70(4):265-270

Universitäts-Hautklinik Kiel, Klinik für Dermatologie, Venerologie und Allergologie, UKSH Kiel, Kiel, Deutschland.

Epidermolysis bullosa acquisita (EBA) is a rare acquired subepidermal bullous autoimmune dermatosis, associated with autoantibodies against collagen type VII, the most important component of dermal anchoring fibrils. Blister induction occurs after binding of autoantibodies to collagen type VII, leading to complement activation, recruitment of neutrophils and secretion of proteases. Clinically, the disease is mostly characterized by tense blisters on trauma-exposed body areas which heal with scarring (mechanobullous form of EBA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-019-4387-7DOI Listing
April 2019
1 Read

MONOCLONAL ANTIBODY THERAPIES for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management?

J Clin Aesthet Dermatol 2019 Feb 1;12(2):39-41. Epub 2019 Feb 1.

Dr. Del Rosso is Research Director of JDR Dermatology Research in Las Vegas, Nevada; is with Thomas Dermatology in Las Vegas, Nevada; and is Adjunct Clinical Professor (Dermatology) with Touro University Nevada in Henderson, Nevada.

Atopic dermatitis (AD) is a chronic disorder that requires thorough patient education and a therapeutic management strategy designed to control flares, decrease recurrences, and reduce pruritus. In cases that cannot be controlled by proper skin care and barrier repair, topical therapy, and avoidance of triggers, systemic therapy is often required to control flares and maintain remission. It is important for clinicians to avoid becoming overly dependent on the intermittent use of systemic corticosteroid therapy to control flares, without incorporating other treatment options that might more optimally control AD over time. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415707PMC
February 2019

Treatment-resistant prurigo nodularis: challenges and solutions.

Clin Cosmet Investig Dermatol 2019 28;12:163-172. Epub 2019 Feb 28.

Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA,

Prurigo nodualris (PN) is a chronic condition with highly pruritic, hyperkeratotic papules or nodules arising in the setting of chronic pruritus. While PN may serve as a phenotypic presentation of several underlying conditions such as atopic dermatitis, chronic kidney disease-related pruritus, and neurological diseases, it represents a distinct clinical entity that may persist despite the removal of the underlying cause, if one is identified. Neuronal proliferation, eosinophils, mast cells, and small-fiber neuropathy play a role in the production of pruritus in PN, although the exact mechanism has not yet been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CCID.S188070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400231PMC
February 2019
4 Reads

[Post-marketing safety analysis of inactivated enterovirus A71 vaccines].

Zhonghua Yu Fang Yi Xue Za Zhi 2019 Mar;53(3):262-266

Institute for Immunization and Prevention, Zhejiang Provincial Center of Disease Control and Prevention, Hangzhou 310051, China.

To evaluate the safety of inactivated enterovirus A71(EV-A71) vaccines after large-scale immunization in the community. We selected EV-A71 susceptible people (healthy children) aged 6-59 months in vaccination clinics from 89 counties in Zhejiang Province between April 2016 and March 2018. All local and systematic adverse actions were collected by 30 min on-site inspection, within 3 days and 4-30 days follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-9624.2019.03.005DOI Listing
March 2019
5 Reads

[Post-marketing observation on safety of inactivated enterovirus A71 vaccine (human diploid cell)].

Zhonghua Yu Fang Yi Xue Za Zhi 2019 Mar;53(3):258-261

Department of Immunization Program, Zhejiang Provincal Center for Disease Control and Prevention, Hangzhou 310051, China.

To evaluate the post-marketing safety of inactivated Enterovirus type 71 (EV-A71) vaccine (human diploid cell) . A total of 20 191 healthy children aged 6 to 59 months were invited to receive 2 doses of EV-A71 vaccine in Zhejiang Province from September 2016 to December 2017. Child caregivers were followed up on the 4(th) or 5(th) day after each EV-A71 vaccination, and the incidence of local, systemic, and other adverse events within 3 days after vaccination was recorded to assess vaccine safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-9624.2019.03.004DOI Listing
March 2019
5 Reads

Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice

J Drugs Dermatol 2019 02;18(2):122-129

Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects around 13% of children and 7% of adults in the US. It can have a significant impact on the quality of life (QoL) of affected individuals due to pruritus and the visibility of lesions on the skin. AD is increasingly recognized as a systemic disease, since dysregulation of the adaptive and innate immune systems plays a key role in the underlying disease pathogenesis, which has important implications for how the condition is treated. Read More

View Article

Download full-text PDF

Source
February 2019
1 Read

Clinicopathological findings and clinical outcomes in 49 cases of feline pemphigus foliaceus examined in Northern California, USA (1987-2017).

Vet Dermatol 2019 Feb 18. Epub 2019 Feb 18.

Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, One Shields Avenue, Davis, CA, 95616, USA.

Background: Few studies have described the pathophysiology, clinical course, treatment outcomes and quality of life (QoL) of cats with pemphigus foliaceus (PF).

Objective: Describe clinicopathological features, treatment outcomes and impacts on QoL in feline PF.

Animals: Forty-nine client-owned cats with PF that presented to a veterinary teaching hospital between 1987 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vde.12731DOI Listing
February 2019

Health-related quality of life and costs in Sjögren's syndrome.

Rheumatology (Oxford) 2019 Feb 15. Epub 2019 Feb 15.

National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.

Health-related quality of life (HRQoL) has an increasing role in medical decision-making. This review of the literature aims to provide an overview on HRQoL, costs, and work disability in SS, a disease characterized by focal lymphocytic infiltration of exocrine glands with no therapeutics of proven immunomodulatory potential. HRQoL is markedly reduced in SS in multiple studies across many countries when compared with HRQoL in healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key370DOI Listing
February 2019
10 Reads

Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management.

Biomed Res Int 2019 15;2019:1268430. Epub 2019 Jan 15.

Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Scalp pruritus is a frequent problem encountered in dermatological practice. This disorder is caused by various underlying diseases and is a diagnostic and therapeutic challenge. Scalp pruritus may be localized to the scalp or extended to other body areas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/1268430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350598PMC
January 2019
1 Read

Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019.

Int Arch Allergy Immunol 2019 8;178(3):207-218. Epub 2019 Feb 8.

Institute of Pharmacology, University of Bern, Bern, Switzerland.

Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting with recurrent eczematous lesions and intense pruritus. It is common and affects both children and adults, often beginning in infancy. Due to the unpredictable disease course, its visible skin lesions, itching and scratching followed by sleeplessness, other associated atopic diseases, and behavioral and psychiatric disorders, AD is an immense burden for patients and caregivers. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497383
Publisher Site
http://dx.doi.org/10.1159/000497383DOI Listing
February 2019
9 Reads

Itch in Psoriasis: A New Look at Well-known Subject.

Acta Derm Venereol 2019 Apr;99(4):429-434

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland.

Psoriasis is a chronic inflammatory dermatosis, frequently presenting with chronic itch. This study investigated the prevalence and detailed clinical characteristics of chronic itch in 143 psoriatic patients, with regard to different age groups, comorbidities and pharmacotherapy. Chronic itch was reported by 72% of subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3147DOI Listing
April 2019
3 Reads

Pemphigoid nodularis - rare presentation of bullous pemphigoid: A case report and literature review.

Exp Ther Med 2019 Feb 5;17(2):1132-1138. Epub 2018 Dec 5.

Department of Dermatology, 'Iuliu Hațieganu' University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.

Pemphigoid nodularis (PN) is a rare clinical variant of bullous pemphigoid characterized by the presence of nodular prurigo-like lesions and pemphigoid blisters. The diagnosis is confirmed by direct immunofluorescence (DIF)/ indirect immunofluorescence (IIF) and immunoserology tests. For some patients, with long mean duration of symptoms, the correct diagnosis of PN is delayed because the disease is not recognized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327548PMC
February 2019
2 Reads

Current and emerging biologic and small molecule therapies for atopic dermatitis.

Expert Opin Biol Ther 2019 Apr 7;19(4):367-380. Epub 2019 Feb 7.

a Department of Dermatology, Laboratory of Inflammatory Skin Diseases , Icahn School of Medicine at Mount Sinai , New York , NY , USA.

Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease, yet until recently there were no safe systemic therapies approved for the long-term management of AD in adult patients. A deeper understanding of disease pathogenesis and identification of molecular and cellular changes has resulted in a rapidly evolving pipeline of therapeutics that holds promise for safer long-term control. Areas covered: In this review, we highlight the growing arsenal of biologic and small molecule antagonists that target pathways implicated in AD pathogenesis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14712598.2019.1
Publisher Site
http://dx.doi.org/10.1080/14712598.2019.1573422DOI Listing
April 2019
6 Reads

Current treatment strategies in refractory chronic pruritus.

Curr Opin Pharmacol 2018 Dec 6;46:1-6. Epub 2018 Dec 6.

Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.

Chronic pruritus is a highly prevalent, debilitating disease, which is often refractory to conventional therapies. A step-wise, guideline-driven approach should be adopted in the management of these patients. Emollients as well as topical corticosteroids if appropriate should be initiated whilst looking for the cause underlying the pruritus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2018.11.007DOI Listing
December 2018
5 Reads

Dermatologic manifestations in end stage renal disease.

Hemodial Int 2019 Jan 6;23(1):3-18. Epub 2018 Dec 6.

Department of Nephrology, Cleveland Clinic Akron General, Akron, Ohio, USA.

Skin manifestations are commonly seen in end stage renal disease (ESRD). Skin involvement in this population can be extensive and dramatically worsen quality of life. Close observation of the skin and nails of ESRD patients by clinicians allows for timely diagnosis and treatment, which ultimately improves quality of life and reduces mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hdi.12689DOI Listing
January 2019
7 Reads

Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients.

Ann Allergy Asthma Immunol 2019 Mar 1;122(3):318-330.e3. Epub 2018 Dec 1.

The Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York; Department of Dermatology, the Laboratory for Inflammatory Skin Diseases, and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address:

Background: Atopic dermatitis (AD) predominantly affects young children, but our understanding of AD pathogenesis is based on skin and blood samples from long-standing adult AD. Genomic biopsy profiling from early pediatric AD showed significant Th2 and Th17/Th22-skewing, without the characteristic adult Th1 up-regulation. Because obtaining pediatric biopsies is difficult, blood gene expression profiling may provide a surrogate for the pediatric skin signature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2018.11.025DOI Listing
March 2019
5 Reads

The Therapeutic Potential of Cannabinoids in Dermatology

Skin Therapy Lett 2018 11;23(6):1-5

Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA

Cannabinoids have demonstrated utility in the management of cancer, obesity, and neurologic disease. More recently, their immunosuppressive and anti-inflammatory properties have been identified for the treatment of several dermatologic conditions. This review thus assesses the therapeutic potential of phytocannabinoids, endoocannabinoids, and chemically synthetic cannabinoids in the management of cutaneous disease. Read More

View Article

Download full-text PDF

Source
November 2018
5 Reads

Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.

JAMA Dermatol 2018 Nov 28. Epub 2018 Nov 28.

Department of Dermatology, University of California, Irvine.

Importance: Dermatology is encountering increasing rates of autoimmune disease manifesting in primary skin conditions that are difficult to treat without a risk of immunosuppression. Naltrexone is an orally active opioid antagonist that influences a variety of systemic pathways, including the immune system, in low doses of 1.5 to 4. Read More

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2018.4093DOI Listing
November 2018
26 Reads

Use of antiepileptic mood stabilizers in dermatology.

Clin Dermatol 2018 Nov - Dec;36(6):756-764. Epub 2018 Aug 16.

Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Several antiepileptic drugs (AEDs) are approved by the US Food and Drug Administration for the treatment of bipolar disorder (valproic acid, divalproex, lamotrigine, carbamazepine) and some cutaneous neuropathic pain syndromes (carbamazepine, gabapentin, pregabalin). The AEDs may be effective in the management of (1) chronic pruritus, including pruritus due systemic disease, including uremia, neuropathic pain, neuropathic pruritus, and complex cutaneous sensory syndromes, especially where central nervous system (CNS) sensitization plays a role; (2) management of emotional dysregulation and the resultant repetitive self-excoriation or other cutaneous self-injury in patients who repetitively stimulate or manipulate their integument to regulate emotions (prurigo nodularis, lichen simplex chronicus, skin picking disorder, trichotillomania); (3) management of dermatologic clinical manifestations associated with autonomic nervous system activation (hyperhidrosis, urticaria, flushing; these often occur in conjunction with psychiatric disorders with prominent autonomic activation and dysregulation, eg, social anxiety disorder, posttraumatic stress disorder); and (4) when certain anticonvulsants have a direct therapeutic effect (eg, in psoriasis); currently the use of AEDs for such cases is largely experimental. Gabapentin (dosage range 300-3600 mg daily) is the most widely studied AED mood stabilizer in dermatology and is especially effective in situations where CNS sensitization is a mediating factor. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0738081X183017
Publisher Site
http://dx.doi.org/10.1016/j.clindermatol.2018.08.005DOI Listing
March 2019
23 Reads

Use of maropitant for the control of pruritus in non-flea, non-food-induced feline hypersensitivity dermatitis: an open-label uncontrolled pilot study.

J Feline Med Surg 2018 Nov 14:1098612X18811372. Epub 2018 Nov 14.

3 University of Liège Veterinary Faculty, Small Animal Internal Medicine Service - Dermatology, Liège, Belgium.

Objectives: Non-flea, non-food-induced hypersensitivity dermatitis (NFNFIHD) is a common inflammatory and pruritic skin disease in cats. When avoidance and conventional systemic immunosuppressive treatments fail to control the clinical signs, there are limited treatment options. The aim of this study was to evaluate the efficacy and tolerability of maropitant in feline NFNFIHD. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1098612X18811372
Publisher Site
http://dx.doi.org/10.1177/1098612X18811372DOI Listing
November 2018
23 Reads

Novel drugs for the treatment of chronic pruritus.

Expert Opin Investig Drugs 2018 12 19;27(12):981-988. Epub 2018 Nov 19.

a Department of Dermatology and Center for Chronic Pruritus , University Hospital Münster , Münster , Germany.

Introduction: Chronic pruritus (CP) is a multidimensional condition severely affecting the quality of life of those affected. Although a multitude of topical and systemic agents are recommended for CP of different origins, the condition often remains refractory to treatment. However, a deeper understanding of the pathophysiology of CP is leading to the development of novel antipruritic drugs. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2018.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2018.1548606DOI Listing
December 2018
25 Reads

Generalized rash and pruritus in a 58-year-old woman.

Allergy Asthma Proc 2018 Nov;39(6):468-471

From the Section of Allergy and Immunology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.

Although allergists often evaluate rashes associated with allergic, IgE mediated etiologies, it is important to consider a wide range of differential diagnoses that includes inflammatory, infectious, and autoimmune etiologies. The case of a 58-year-old woman with a 1-year history of progressive pruritic rash that did not improve with topical creams and steroids is presented. The patient did not state any other symptoms, and a physical examination was notable for a widespread rash. Read More

View Article

Download full-text PDF

Source
http://www.ingentaconnect.com/content/10.2500/aap.2018.39.41
Publisher Site
http://dx.doi.org/10.2500/aap.2018.39.4181DOI Listing
November 2018
12 Reads

Exploratory Study of Intracutaneous Histamine Stimulation in Patient Populations with Chronic Pruritus.

Acta Derm Venereol 2019 Mar;99(3):291-297

vDepartment of Dermatology, University Hospital Muenster, Von-Esmarch-Str. 58, DE-48149 Münster, Germany.

Chronic pruritus can be a diagnostic sign of an underlying disease. In the intracutaneous histamine test, histamine (one of the best-known inducers of pruritus) may cause different reaction patterns depending on the underlying disease. The aim of this study was to determine if an intracutaneous injection of histamine can differentiate between the causes of chronic pruritus and thus be used as a diagnostic test in chronic pruritus of unknown aetiology. Read More

View Article

Download full-text PDF

Source
http://www.medicaljournals.se/acta/content/abstract/10.2340/
Publisher Site
http://dx.doi.org/10.2340/00015555-3078DOI Listing
March 2019
3 Reads

Effects of acupuncture on chronic idiopathic pruritus: an uncontrolled pilot study evaluating inflammatory changes with treatment.

J Complement Integr Med 2018 Nov 3. Epub 2018 Nov 3.

Medical Acupuncture, Ahn Clinic, Scottsdale, AZ, USA.

Background Conduct a pilot study addressing the efficacy of acupuncture in the treatment of chronic idiopathic pruritus to aid in the design of a larger clinical trial. Routine laboratory tests to assess systemic inflammation in addition to subjective patient surveys were performed provide documentation of efficacy of treatment. Methods Patients with chronic pruritus who did not respond to standard treatment were recruited to participate. Read More

View Article

Download full-text PDF

Source
http://www.degruyter.com/view/j/jcim.ahead-of-print/jcim-201
Publisher Site
http://dx.doi.org/10.1515/jcim-2018-0021DOI Listing
November 2018
10 Reads

Itching, chloroquine, and malaria: a review of recent molecular and neuroscience advances and their contribution to mechanistic understanding and therapeutics of chronic non-histaminergic pruritus.

Int J Dermatol 2018 Oct 26. Epub 2018 Oct 26.

Department of Medicine, Division of Clinical Pharmacology, Baylor College of Medicine, Houston, TX, USA.

Chloroquine (CQ) is an antimalarial drug that elicits severe pruritus in black Africans with malaria fever. This acute itching (2-7 days duration) exhibits age dependency and a racial and genetic predilection. CQ itch is non-histaminergic, which makes it both a good model and a tool to probe the mechanisms of chronic itch. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ijd.14252
Publisher Site
http://dx.doi.org/10.1111/ijd.14252DOI Listing
October 2018
25 Reads

Leukotriene receptor antagonists for eczema.

Cochrane Database Syst Rev 2018 10 21;10:CD011224. Epub 2018 Oct 21.

Department of Dermatology, St Helier Hospital, Wrythe Lane, Carshalton, Surrey, UK, SM5 1AA.

Background: Eczema is a common, chronic, inflammatory skin condition that is frequently associated with atopic conditions, including asthma. Leukotriene receptor antagonists (LTRAs) have a corticosteroid-sparing role in asthma, but their role in eczema remains controversial. Currently available topical therapies for eczema are often poorly tolerated, and use of systemic agents is restricted by their adverse effect profile. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD011224.pub2
Publisher Site
http://dx.doi.org/10.1002/14651858.CD011224.pub2DOI Listing
October 2018
16 Reads

Atopic dermatitis.

Allergy Asthma Clin Immunol 2018 12;14(Suppl 2):52. Epub 2018 Sep 12.

2Department of Pediatrics, University of Alberta, Edmonton, AB Canada.

Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of affected individuals as well as their families. Although the pathogenesis of the disorder is not completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient's history and clinical manifestations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13223-018-0281-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157251PMC
September 2018
2 Reads

Systemic Treatment for Severe Atopic Dermatitis.

Arch Immunol Ther Exp (Warsz) 2019 Apr 22;67(2):69-78. Epub 2018 Aug 22.

Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, Artur Ramos 178 ap.211A, Jd. América, São Paulo, SP, CEP: 01454-904, Brazil.

Atopic dermatitis (AD) is a chronic inflammatory, relapsing disease of the skin, characterized by intense pruritus, maculopapular or vesicular erythematous lesions and scaling, sometimes accompanied by oozing, crusts and/or lichenification that has a negative impact on patients' quality of life. Prevalence is higher in children, around 15%, and approximately 5% in adults. Before introducing systemic therapy, it is mandatory to review patients' adherence to the correct use of topical treatments (corticosteroids, calcineurin inhibitors or cresoborole) and/or phototherapy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00005-018-0521-y
Publisher Site
http://dx.doi.org/10.1007/s00005-018-0521-yDOI Listing
April 2019
11 Reads

Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety.

Vet Rec 2018 Dec 29;183(21):654. Epub 2018 Aug 29.

Laboratory of Bioengineering and Tissue Regeneration (LABRET), Department of Cell Biology, Genetics and Physiology, Faculty of Sciences, University of Málaga, IBIMA, Málaga, Spain.

Canine atopic dermatitis (AD) is a common skin disease with a 10-15 per cent prevalence. Current treatments vary in their efficacy and safety. The immunomodulatory properties of mesenchymal stem cells (MSCs) make them a promising alternative treatment. Read More

View Article

Download full-text PDF

Source
http://veterinaryrecord.bmj.com/lookup/doi/10.1136/vr.104867
Publisher Site
http://dx.doi.org/10.1136/vr.104867DOI Listing
December 2018
13 Reads

Xerosis cutis and associated co-factors in women with prurigo nodularis.

An Bras Dermatol 2018 Sep-Oct;93(5):671-679

Department of Dermatology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.

Background: Current data regarding the associated factors of prurigo nodularis are still uncertain, except for atopic predisposition.

Objectives: The purposes of this study were to (1) determine the frequencies of xerosis and other accompanying diseases of female patients with prurigo nodularis; (2) compare the demographic, clinical and accompanying disease characteristics by grouping these patients according to whether they have associated xerosis (who were subsequently subgrouped as atopic or non-atopic) or not.

Methods: In this retrospective descriptive study, 80 females with PN were categorized according to the accompanying diseases (dermatological, systemic, neurological, psychogenic, mixed, or undetermined origin). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20187127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106662PMC
October 2018
6 Reads

Itch suppression in mice and dogs by modulation of spinal α2 and α3GABA receptors.

Nat Commun 2018 08 13;9(1):3230. Epub 2018 Aug 13.

Institute of Pharmacology and Toxicology, University of Zürich, Winterthurerstrasse 190, CH-8057, Zürich, Switzerland.

Chronic itch is a highly debilitating condition affecting about 10% of the general population. The relay of itch signals is under tight control by inhibitory circuits of the spinal dorsal horn, which may offer a hitherto unexploited therapeutic opportunity. Here, we found that specific pharmacological targeting of inhibitory α2 and α3GABA receptors reduces acute histaminergic and non-histaminergic itch in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-05709-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089996PMC
August 2018
10 Reads

Health-related quality of life in patients with cutaneous T-cell lymphoma?

Int J Dermatol 2018 Nov 3;57(11):1314-1319. Epub 2018 Aug 3.

Departments of Dermatology and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Background: Little is currently known about health-related quality of life (HRQoL) of patients with cutaneous T-cell lymphoma (CTCL), a condition characterized by chronic, pruritic, visible lesions, features which may be uniquely influential.

Objective: The aim of this study was to establish baseline HRQoL data for patients with CTCL and identify its influencing factors.

Methods: Prospective, nonblinded survey design utilizing questionnaires including panels of QoL indices obtained from 105 patients with mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14132DOI Listing
November 2018
9 Reads

Neurodystrophic Hand Dermatitis: Sannino Barduagni Syndrome.

Acta Dermatovenerol Croat 2017 Dec;25(4):312-313

lisa Moliterni, MD 2Sapienza University of Rome, Umberto I Polyclinic, Dermatology Department Viale del Policlinico 156 00186 Rome Italy

Hand eczema is a chronic disease (1), commonly considered the expression of a contact allergic or irritative dermatitis. However, when the prick/patch tests and laboratory investigations are negative, important diagnostic challenges may arise. Peripheral nerve fibers are in fact capable of releasing neuromediators. Read More

View Article

Download full-text PDF

Source
December 2017
24 Reads

Less common rheumatologic disorders: Current concepts of skin and systemic manifestations.

Authors:
Taraneh Paravar

Clin Dermatol 2018 Jul - Aug;36(4):525-532. Epub 2018 Apr 10.

Department of Dermatology, University of California-San Diego School of Medicine, San Diego, California, USA. Electronic address:

The cutaneous manifestations of the common rheumatologic disorders, such as systemic lupus erythematosus, dermatomyositis, and systemic sclerosis, are well known. In contrast, the dermatologic findings of less common rheumatologic disorders, including Sjögren syndrome, mixed connective tissue disease, and relapsing polychondritis, are less widely known. The cutaneous manifestations of these connective tissue disorders are reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2018.04.009DOI Listing
December 2018
4 Reads

Systemic sclerosis: Current concepts of skin and systemic manifestations.

Clin Dermatol 2018 Jul - Aug;36(4):459-474. Epub 2018 Apr 12.

Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Systemic sclerosis is an uncommon autoimmune connective tissue disease with multiorgan system involvement and significant associated morbidity and mortality. Cutaneous signs and clinical manifestations are of particular importance, as they may be recognized before systemic manifestations, allowing earlier risk stratification into the limited and diffuse cutaneous subtypes, as well as earlier initiation of treatment. Important cutaneous manifestations include Raynaud's phenomenon, digital ulcers, cutaneous sclerosis, calcinosis cutis, telangiectasias, pruritus, and dyspigmentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2018.04.004DOI Listing
December 2018
13 Reads

Chronic generalized pruritus without primary skin lesions: a longitudinal prospective observational study.

Int J Dermatol 2019 Mar 24;58(3):273-278. Epub 2018 Jul 24.

Skin Research Center, Department of Dermatology, Razi hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.

Pruritus is among the most common complaints in the field of dermatology. It is also a disturbing symptom of many systemic disorders. Chronic pruritus (CP) refers to the cases of the symptom which last longer than 6 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14125DOI Listing
March 2019
18 Reads

Clinical presentation, management, and pathophysiology of neuropathic itch.

Lancet Neurol 2018 08 17;17(8):709-720. Epub 2018 Jul 17.

Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Unlike conventional itch, neuropathic itch develops in normal skin from excess peripheral firing or dampened central inhibition of itch pathway neurons. Neuropathic itch is a symptom of the same central and peripheral nervous system disorders that cause neuropathic pain, such as sensory polyneuropathy, radiculopathy, herpes zoster, stroke, or multiple sclerosis, and lesion location affects symptoms more than aetiology. The causes of neuropathic itch are heterogeneous, and thus diagnosis is based primarily on recognising characteristic, disease-specific clinical presentations. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14744422183021
Publisher Site
http://dx.doi.org/10.1016/S1474-4422(18)30217-5DOI Listing
August 2018
27 Reads

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis.

Am J Clin Dermatol 2018 Aug;19(4):617-624

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Dupilumab (Dupixent), a subcutaneously administered, fully human IgG4 monoclonal antibody directed against the IL (interleukin)-4 receptor α subunit, blocks the signalling of IL-4 and IL-13, two T helper cell type 2 cytokines implicated in the immunopathology of atopic dermatitis (AD). It is the first biologic therapy to have been approved for the treatment of adult patients with moderate-to-severe AD in the EU and USA. In phase III trials in adults with moderate-to-severe AD who were inadequately controlled with topical medications and/or systemic treatments, such as ciclosporin, or for whom these therapies were not advisable, 16 weeks' treatment with dupilumab as monotherapy or in combination with topical corticosteroids (TCS) improved multiple measures of disease severity, pruritus, sleep disturbance, anxiety and depression, and quality of life compared with placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0370-9DOI Listing
August 2018
6 Reads

A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.

Oncologist 2018 Oct 17;23(10):1119-1126. Epub 2018 Jul 17.

Department of Dermatology, Columbia University Medical Center, New York, New York, USA

Immunotherapy has emerged as a highly effective treatment for numerous cancers. Use of checkpoint inhibitors against various molecules including programmed cell death protein-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 have become widespread in clinical practice. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions known collectively as immune-related adverse events (irAEs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263133PMC
October 2018
45 Reads

Pemphigus herpetiformis in South Tunisia: a clinical expression of pemphigus foliaceus?

Int J Dermatol 2018 Sep 16;57(9):1094-1101. Epub 2018 Jul 16.

Immunology Department, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia.

Background: Pemphigus herpetiformis (PH) is a rare subtype of pemphigus combining clinical features of dermatitis herpetiformis and the immunopathologic characteristics of pemphigus. We aimed to analyze the epidemiological, clinical, and immunological presentation and management of the disease in a cohort of south Tunisian patients with a long-term follow-up.

Methods: We included all patients with confirmed PH followed from January 1987 to December 2015 in the dermatology department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14139DOI Listing
September 2018
12 Reads